# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an ...
Piper Sandler analyst Yasmeen Rahimi maintains Verona Pharma (NASDAQ:VRNA) with a Overweight and raises the price target fro...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...
Wedbush analyst Liana Moussatos reiterates Verona Pharma (NASDAQ:VRNA) with a Outperform and maintains $33 price target.
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...
Under the terms of the debt facility, the Company drew $50 million at closing, and may draw, subject to certain conditions prec...